Surgery doesn't up pediatric neuroblastoma outcomes

January 15, 2013
Surgery doesn't up pediatric neuroblastoma outcomes
For pediatric patients with stage 4 neuroblastoma, surgery of the primary tumor site has no impact on outcomes, according to a study published online Jan. 2 in the Journal of Clinical Oncology.

(HealthDay)—For pediatric patients with stage 4 neuroblastoma, surgery of the primary tumor site has no impact on outcomes, according to a study published online Jan. 2 in the Journal of Clinical Oncology.

Thorsten Simon, M.D., from the University of Cologne in Germany, and colleagues reviewed operation notes and imaging reports from 278 patients with stage 4 neuroblastoma (age 18 months or older at diagnosis) participating in a prospective clinical trial.

The researchers found that at diagnosis there were image-defined risk factors that were significantly predictive for the extent of at first and best operation. Before chemotherapy, 6.1 percent of participants underwent complete resection, 5.0 percent underwent incomplete resection, and 88.5 percent underwent biopsy or no surgery. Following , 54.7, 30.6, and 13.3 percent underwent complete resection, incomplete resection, and only biopsy or no surgery of the primary tumor, respectively. The extent of first or best operation had no effect on event-free survival, local progression-free survival, or overall survival.

"In conclusion, the results of this study do not justify aggressive surgery in patients undergoing high-intensity multimodal treatment for metastatic neuroblastoma," the authors write. "Future trials are required to determine whether even less surgery might be adequate in high-intensity multimodal treatment of metastatic neuroblastoma and if biologic factors are correlated with the respectability of the primary tumor."

Explore further: Early response is an indicator for rectal cancer survival

More information: Abstract
Full Text (subscription or payment may be required)

Related Stories

Early response is an indicator for rectal cancer survival

April 10, 2012

(HealthDay) -- In patients with locally advanced rectal cancer undergoing radical resection, response to neoadjuvant chemoradiotherapy is an early marker that correlates with rates of recurrence-free survival, distant metastases, ...

Gender, BMI impact bladder perforation during resection

April 17, 2012

(HealthDay) -- For patients with bladder tumors, female gender, low body mass index, and tumor characteristics correlate with the risk of bladder perforation during transurethral resection, according to research published ...

High survival with surgery in low-risk neuroblastoma

April 25, 2012

(HealthDay) -- Surgery alone results in high five-year event-free and overall survival (EFS and OS) rates for patients with low-risk stage 2a and 2b neuroblastoma (NBL), according to research published online April 23 in ...

Pre-op chemoradiotherapy ups survival in esophageal cancer

May 31, 2012

(HealthDay) -- For patients with esophageal or esophagogastric-junction cancer, treatment with neoadjuvant chemoradiotherapy followed by surgical resection is associated with improved survival compared with surgery alone, ...

Nonoperative approach feasible in advanced colon cancer

August 9, 2012

(HealthDay) -- Treating patients with surgically unresectable metastatic colon cancer and an asymptomatic intact primary tumor with bevacizumab and infusional fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) chemotherapy ...

Recommended for you

Researchers thwart cancer cells by triggering 'virus alert'

August 27, 2015

Working with human cancer cell lines and mice, researchers at the Johns Hopkins Kimmel Cancer Center and elsewhere have found a way to trigger a type of immune system "virus alert" that may one day boost cancer patients' ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.